Related Experiment Video
Updated: Sep 17, 2026

Immunometabolic Circuits in Infection for Advancing Host Directed Therapies
Published on: September 13, 2024
Leishmania inhibits NLRP3 expression through IL-33/ST2 signaling driven SOCS1-mediated p65 degradation
Souravi Roy1, Mayumi Mandal1, Madhurima Banerjee2
1Department of Biochemistry, University of Calcutta, Kolkata, India.
Abstract:
The dynamic interplay between pro- and anti-inflammatory cytokines plays a crucial role in regulating host immune responses. In our earlier study, we showed that Leishmania donovani-induced IL-33 destabilizes host cytokine dynamics by downregulating TNF-α and IL-12 and ensures intramacrophage parasite survival. Another pertinent host favorable proinflammatory cytokine is Il-1β, maturation of which depends on the activation of NLRP3 inflammasome complex. Our present study highlights that independent neutralization of IL-33 and its receptor ST2, resulted in elevated levels of NLRP3 both at messenger RNA and protein levels, along with increased levels of mature IL-1β. Reduced NLRP3 expression during infection was correlated with decreased protein levels of p65, the major subunit of NF-κB transcription factor complex. An unaltered transcript level of p65 in infected macrophages along with reduced protein expression suggested that post-translational modification and ubiquitination-mediated p65 degradation in the presence of IL-33 was found to be driven by the ubiquitin ligase SOCS1. Administration of IL-33-neutralizing antibody in infected mice resulted in enhanced expression of both p65 and NLRP3, along with increased production of TNF-α, IL-12, and IL-1β, suggesting that IL-33 regulates these cytokines through a shared intermediary, p65. Neutralizing IL-33 during infection led to a reduction in SOCS1 expression, and SOCS1 knockdown by targeted short hairpin RNA in infected mice restores p65 levels, reactivates NLRP3 expressions, and reduces parasite burden in the visceral organs. This study highlights the IL-33/SOCS1 pathway as a potential target for host-directed therapeutic strategies aimed at restoring protective immunity during chronic leishmaniasis.
Related Concept Videos
Antiprotozoal Agents
Leishmaniasis
